Maxim Ups It's Target on KERX From $9 To $ 12 LINKED
Seeking Alpha Market Currents 7/31/13
real-time news and commentary for investors
All Market Currents
Thursday, Aug 1
Maxim ups its price target on Keryx Pharmaceutical to $12
Maxim Group raises its price target on Keryx Biopharmaceutical (KERX -1.2%) to $12 from $9. The firm says the boost is driven by the company's encouraging data packages, near-term filings in the U.S. and E.U. and the potential upside in the pre-dialysis marketplace.